Scientific article
Open access

Management of the thrombotic risk associated with COVID-19: guidance for the hemostasis laboratory

Published inThrombosis Journal, vol. 18, no. 17
Publication date2020

Coronavirus disease 2019 (COVID-19) is associated with extreme inflammatory response, disordered hemostasis and high thrombotic risk. A high incidence of thromboembolic events has been reported despite thromboprophylaxis, raising the question of a more effective anticoagulation. First-line hemostasis tests such as activated partial thromboplastin time, prothrombin time, fibrinogen and D-dimers are proposed for assessing thrombotic risk and monitoring hemostasis, but are vulnerable to many drawbacks affecting their reliability and clinical relevance. Specialized hemostasis-related tests (soluble fibrin complexes, tests assessing fibrinolytic capacity, viscoelastic tests, thrombin generation) may have an interest to assess the thrombotic risk associated with COVID-19. Another challenge for the hemostasis laboratory is the monitoring of heparin treatment, especially unfractionated heparin in the setting of an extreme inflammatory response. This review aimed at evaluating the role of hemostasis tests in the management of COVID-19 and discussing their main limitations.

  • Anticoagulation
  • COVID-19
  • Coagulopathy
  • D-dimers
  • Fibrinolysis
  • Hemostasis
  • Heparin
  • Thrombin generation
  • Thrombosis
  • Viscoelastic tests
Citation (ISO format)
HARDY, M et al. Management of the thrombotic risk associated with COVID-19: guidance for the hemostasis laboratory. In: Thrombosis Journal, 2020, vol. 18, n° 17. doi: 10.1186/s12959-020-00230-1
Main files (1)
Article (Published version)
ISSN of the journal1477-9560

Technical informations

Creation01/25/2021 11:14:00 AM
First validation01/25/2021 11:14:00 AM
Update time03/16/2023 12:04:58 AM
Status update03/16/2023 12:04:57 AM
Last indexation02/12/2024 12:01:59 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack